Fosaprepitant versus Ondansetron for prevention of postoperative nausea and vomiting in oral and maxillofacial surgery

Fosaprepitant versus Ondansetron for prevention of postoperative nausea and vomiting in oral and maxillofacial surgery - Fosaprepitant versus Ondansetron for prevention of PONV

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018532

Enrollment

Registered

2015-10-10

Start date

2015-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Fosaprepiitant group takes fosaprepitant 150mg div before induction os anesthesia. Ondansetron group takes ondansetron 4mg div before induction os anesthesia.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients meet the criteria of the ASA PS 1-3, who are received oral surgery.

Exclusion criteria

Exclusion criteria: ASA PS over IV. Take other antiemetics. Containdication to fosaprepitant or ondansetron.

Design outcomes

Primary

Measure	Time frame
frequency of the postoperative vomiting/nausea.	—

Countries

Japan

Contacts

Public ContactYasuo Tsutsumi

Tokushima University Hospital Anesthesiology

tsutsumi@tokushima-u.ac.jp088-633-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026